RyosukeTsugitomi· @Rtsugitom · X·· 1 day agoScore70
Body
A much larger difference than anticipated!
#ESMO26
18 views · 0 likes · 0 reposts · 1 reply
Two highly anticipated studies will be presented at today's Presidential Symposium #ESMO26 ① KRASCENDO-1: Results from a head-to-head trial comparing two KRAS inhibitors in patients with KRAS G12C-mutated NSCLC在 X 查看被引用的帖子
Replies in this thread
- RyosukeTsugitomi@Rtsugitom
Is sotorasib becoming the crizotinib eventually superseded by a newer inhibitor, just as alectinib replaced crizotinib in ALK-positive NSCLC..? Thank you sotorasib, for the past. All glory to divarasib, the future!
Source: RyosukeTsugitomi · x.com